Bullous pemphigoid in a patient treated with nivolumab

被引：6
作者：
Cuenca-Barrales, Carlos [1 ]
Espadafor-Lopez, Beatriz [2 ]
Martinez-Lopez, Antonio [2 ]
Cancela-Diez, Barbara [3 ]
Ruiz-Villaverde, Ricardo [1 ]
机构：
[1] Hosp Univ San Cecilio, Dermatol Dept, Granada, Spain
[2] Hosp Univ Virgen Nieves, Dermatol Dept, Granada, Spain
[3] Hosp Univ San Cecilio, Pharm Unit, Granada, Spain
来源：
DERMATOLOGIC THERAPY | 2019年 / 32卷 / 05期
关键词：
IMMUNE CHECKPOINT BLOCKADE;
D O I：
10.1111/dth.13030
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
    Chen, Jonathan H.
    Pezhouh, Maryam K.
    Lauwers, Gregory Y.
    Masia, Ricard
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (05) : 643 - 654
  • [2] Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy
    Cuenca-Barrales, Carlos
    Lopez-Delgado, David
    Cancela-Diez, Barbara
    Galvez-Moreno, Marina
    Ruiz-Villaverde, Ricardo
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (07) : E33 - E34
  • [3] Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
    Curry, Jonathan L.
    Tetzlaff, Michael T.
    Nagarajan, Priyadharsini
    Drucker, Carol
    Diab, Adi
    Hymes, Sharon R.
    Duvic, Madeleine
    Hwu, Wen-Jen
    Wargo, Jennifer A.
    Torres-Cabala, Carlos A.
    Rapini, Ronald P.
    Prieto, Victor G.
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (02) : 158 - 176
  • [4] A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
    Fessas, Petros
    Lee, Hassal
    Ikemizu, Shinji
    Janowitz, Tobias
    [J]. SEMINARS IN ONCOLOGY, 2017, 44 (02) : 136 - 140
  • [5] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, J. M.
    Bigenwald, C.
    Champiat, S.
    Collins, M.
    Carbonnel, F.
    Postel-Vinay, S.
    Berdelou, A.
    Varga, A.
    Bahleda, R.
    Hollebecque, A.
    Massard, C.
    Fuerea, A.
    Ribrag, V.
    Gazzah, A.
    Armand, J. P.
    Amellal, N.
    Angevin, E.
    Noel, N.
    Boutros, C.
    Mateus, C.
    Robert, C.
    Soria, J. C.
    Marabelle, A.
    Lambotte, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
  • [6] Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
    Robert, Caroline
    Ribas, Antoni
    Hamid, Omid
    Daud, Adil
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Hwu, Wen-Jen
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Joseph, Richard W.
    Dronca, Roxana
    Patnaik, Amita
    Zarour, Hassane
    Kefford, Richard
    Hersey, Peter
    Zhang, Jin
    Anderson, James
    Diede, Scott J.
    Ebbinghaus, Scot
    Hodi, F. Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1668 - +
  • [7] Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
    Schadendorf, Dirk
    Wolchok, Jedd D.
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Chesney, Jason
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Walker, Dana
    Bhore, Rafia
    Larkin, James
    Postow, Michael A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3807 - +
  • [8] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Sibaud, Vincent
    Meyer, Nicolas
    Lamant, Laurence
    Vigarios, Emmanuelle
    Mazieres, Julien
    Delord, Jean Pierre
    [J]. CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 254 - 263
  • [9] Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
    Wang, Leo L.
    Patel, Gopal
    Chiesa-Fuxench, Zelma C.
    McGettigan, Suzanne
    Schuchter, Lynn
    Mitchell, Tara C.
    Ming, Michael E.
    Chu, Emily Y.
    [J]. JAMA DERMATOLOGY, 2018, 154 (09) : 1057 - 1061
  • [10] Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature
    Zhao, Cathy Yunjia
    Hwang, Shelley Ji Eun
    Consuegra, Germana
    Chou, Shaun
    Fernandez-Penas, Pablo
    [J]. MELANOMA RESEARCH, 2018, 28 (06) : 491 - 501
1